Brigatinib Patent Expiration
Brigatinib is Used for treating anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC). It was first introduced by Takeda Pharmaceuticals Usa Inc
Brigatinib Patents
Given below is the list of patents protecting Brigatinib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Alunbrig | US10385078 | Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-YL) piperidin-1-YL]phenyl}pyrimidine-2,4-diamine | Nov 10, 2035 | Takeda Pharms Usa |
| Alunbrig | US9012462 | Phosphorous derivatives as kinase inhibitors | Apr 28, 2031 | Takeda Pharms Usa |
| Alunbrig | US9273077 | Phosphorus derivatives as kinase inhibitors | May 21, 2029 | Takeda Pharms Usa |
| Alunbrig | US9611283 | Methods for inhibiting cell proliferation in ALK-driven cancers | Apr 10, 2034 | Takeda Pharms Usa |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳